• 1
    Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. JAMA. 1977;237:255261.
  • 2
    Ong KL, Cheung BM, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999–2004. Hypertension. 2007;49:6975.
  • 3
    Moser M, Franklin SS. Hypertension management: results of a new national survey for the Hypertension Education Foundation: Harris interactive. J Clin Hypertens (Greenwich). 2007;9:316323.
  • 4
    Moser M. Historical perspectives on the management of hypertension. J Clin Hypertens (Greenwich). 2006;8(8, suppl 2):1520.
  • 5
    Moser M. From JNC 1 to JNC 7: what have we learned? Prog Cardiovasc Dis. 2006;48:303315.
  • 6
    Jamerson K, Weber MA, Bakris GL, et al; for the ACCOMPLISH trial investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:24172428.
  • 7
    The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:25602572.
  • 8
    Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet. 2004;363:20492051.
  • 9
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:29812997.
  • 10
    Elliott WJ, Jonsson MC, Black HR. It is not beyond the blood pressure; it is the blood pressure. Circulation. 2006;113:27632772.
  • 11
    Kaiser G, Ackermann R, Sioufi A. Pharmacokinetics of a new angiotensin-converting enzyme inhibitor, benazepril hydrochloride, in special populations. Am Heart J. 1989;117:746751.
  • 12
    Zannad F, Matzinger A, Larche J. Trough/peak ratios of once-daily angiotensin converting enzyme inhibitors and calcium antagonists. Am J Hypertens. 1996;9:633643.
  • 13
    Lipicky RJ. Trough:peak ratio: the rationale behind the United States Food and Drug Administration recommendations. J Hypertens Suppl. 1994;12:S17S18.
  • 14
    Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension. 2004;43:49.
  • 15
    Meredith PA, Elliott HL. Clinical pharmacokinetics of amlodipine. Clin Pharmacokinet. 1992;22:2231.
  • 16
    Hernandez RH, Armas-Hernandez MJ, Chourio JAC, et al. Comparative effects of amlodipine and nifedipine GITS during treatment and after missing two doses. Blood Press Monit. 2001;6:4757.
  • 17
    Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the Hypertension Detection and Follow-up Program I. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA. 1979;242:25622571.
  • 18
    The Multiple Risk Factor Intervention Trial Research Group (MRFIT). Mortality rates after 10.5 years for hypertensive participants in the Multiple Risk Factor Intervention Trial. Circulation. 1990;82:16161628.
  • 19
    SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:32553264.
  • 20
    Neaton JD, Grimm RH Jr, Prineas RJ, et al. Treatment of mild hypertension study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA. 1993;270:713724.
  • 21
    Elliott WJ, Grimm RH Jr. Using diuretics in practice - one opinion. J Clin Hypertens (Greenwich). 2008;10:856862.
  • 22
    Grimm RH Jr, Black H, Rowen R, et al. Amlodipine versus chlorthalidone versus placebo in the treatment of stage I isolated systolic hypertension. Am J Hypertens 2002;15(1 Pt 1):3136.
  • 23
    Sica DA. Chlorthalidone. Has it always been the best thiazide-type diuretic? Hypertension. 2006;47:321322.
  • 24
    Ernst ME, Goerdt CJ, Carter BL, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension. 2006;47:352358.
  • 25
    Finkielman JD, Schwartz GL, Chapman AB, et al. Lack of agreement between office and ambulatory blood pressure responses to hydrochlorothiazide. Am J Hypertens. 2005;18:398402.
  • 26
    Staessen JA, Thijs L, Fagard R, et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA. 1999;282:539546.
  • 27
    Svensson P, De Faire U, Sleight P, et al. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE substudy. Hypertension. 2001;38:e28e32.
  • 28
    Amery A, Birkenhager W, Brixko P, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly Trial. Lancet. 1985;1:13491354.
  • 29
    MRC Working Party. Medical research council trial of treatment of hypertension in older adults: principal results. BMJ. 1992;304:405412.
  • 30
    Borhani NO, Mercuri M, Borhani PA, et al. Final outcome results of the Multi-center Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. JAMA. 1996;276:785791.
  • 31
    Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000;356:366372.
  • 32
    Garg JP, Elliott WJ, Folker A, et al. Resistant hypertension revisited: a comparison of two university-based cohorts. Am J Hypertens. 2005;18(5, pt 1):619626.
  • 33
    Calhoun DA, Jones D, Textor S, et al. American Heart Association Professional Education Committee. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117:e510e526.
  • 34
    Moser M, Setaro JF. Resistant or difficult-to-control hypertension. N Engl J Med. 2006;355:385392.